01:01 PM EDT, 09/05/2024 (MT Newswires) -- Hoth Therapeutics ( HOTH ) shares rose 61% in recent Thursday trading on plans to expand the company's first-in-human phase 2a clinical trial of HT-001 for the treatment of skin toxicities related to epidermal growth factor receptor inhibitors.

The phase 2a dose-ranging study will assess the effectiveness, safety and tolerability of topical HT-001 for addressing skin toxicities caused by EGFRi, the company said Thursday in statement.

The company received institutional review board approval from the Montefiore Medical Center and Dana-Farber Cancer Institute to proceed with the trial.

Price: 1.12, Change: +0.43, Percent Change: +61.24